Opinion|Videos|July 29, 2024

Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

Video content above is prompted by the following:

  • How do mutations associated like STK11, KEAP1, KRAS impact effectiveness of standard therapies and confer resistance? 

  • In real-world clinical practice, how frequently do patients with mNSCLC undergo comprehensive molecular and biomarker testing through techniques like NGS to evaluate for genetic alterations and potential targetable mutations?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo